Upcoming event: Medica Düsseldorf, Germany 14-17 Nov  2022 – Visit our booth Hall 3 / A42

Our Story

Milestones

2010
Established in Oulu, Finland
Global Innovation Network (GIN) is founded in Oulu, Finland.
2011
Headquarters opened in Oulunsalo
2012
Delilah is launched
Modular desktop automation platform Delilah is launched.
2013
First major delivery
Automated reagent dispensing line to Fiomi Diagnostics (now Trinity Biotech). PMB nanolitre dispensing pump is launched.
2014
Acquisition and name change
GIN acquires Sigolis (est. 2007) Sweden for microfluidic technology IPR. Global Innovation Network (GIN) changes name to Ginolis
2015
Expand to USA
Ginolis expands to North America and opens an office in San Diego, USA. Major delivery: Fully automated production line for Tandem Diabetes Care insulin pumps.
2016
Launch and first delivery of revolutionizing Lateral Flow Device Assembly (LFDA) system.
Ginolis expands to North America and opens an office in San Diego, USA. Major delivery: Fully automated production line for Tandem Diabetes Care insulin pumps.
2017
Ginolis expands to China and opens an office in Suzhou.
Ginolis expands to North America and opens an office in San Diego, USA. Major delivery: Fully automated production line for Tandem Diabetes Care insulin pumps.
2018
Product launch
Launch of Pixie, a standard system for automated optical quality inspection.
2019
Distribution agreement and product launch
Ginolis and MDS (Japan) sign a distributor agreement. Ginolis launches a new model of the high precision PMBi dispensing pump. Ginolis expands to the US east coast.
2020
Product launch
Launch of LFDA-1, a semi-automated assembly solution for lateral flow devices.
2021
Ginolis becomes part of CELLINK Group
Since March 2021 we are a proud and happy part of the CELLINK family and we are on the road to success constantly looking for new team members. In August 2021, CELLINK became BICO Group.
Previous
Next

Joined BICO through acquisition in 2021.

Founded in 2016, BICO (formerly CELLINK) is the world’s leading bioconvergence company, organized into three business areas: Biosciences, Bioautomation, and Bioprinting. BICO reduces the organ shortage and speeds up drug development by providing accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry.

 

Using a combination of robotics, artificial intelligence, advanced genomics, and 3D bioprinting, our  innovative technologies enable researchers and practitioners in the life sciences to conduct cell line development in 3D, perform high-throughput drug screening and diagnostics, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. BICO is the future of life-saving treatments, as we enable our customers to improve people’s health and lives.

 

Our products are trusted by more than 2,000 laboratories, including the top 20 pharmaceutical companies. They are being used in more than 65 countries, and have been cited in more than 11,000 publications. BICO is listed on Nasdaq Stockholm under BICO.

Send us your application!

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

We can answer all your questions!